NovoCure Limited filed a current report to highlight a regulatory milestone in Japan. On September 15, 2025, Japan’s Ministry of Health, Labour and Welfare approved NovoCure’s Optune Lua® device for use together with PD-1/PD-L1 inhibitor drugs to treat adult patients with unresectable advanced or recurrent non-small cell lung cancer whose disease has progressed after platinum-based chemotherapy. This expands Optune Lua’s approved treatment setting in Japan for a difficult-to-treat lung cancer population. The company released the news in a press release that is furnished as an exhibit to the report.
NovoCure (NVCR) insider purchase by CEO Ashley Cordova: The filing reports that on 09/05/2025 the reporting person purchased 81,550 ordinary shares in multiple trades at prices ranging from $12.02 to $12.47, with a weighted average price of $12.2239. After the purchases, the reporting person beneficially owned 437,569 shares. The Form 4 identifies Ashley Cordova as Chief Executive Officer and a director, and the filing was signed by an attorney-in-fact on 09/08/2025. The filer notes willingness to provide detailed trade-level prices and quantities on request.
NovoCure Limited reported that its subsidiary Novocure GmbH has decided to terminate the LUNAR-4 clinical trial. LUNAR-4 is a phase 2, single-arm, open-label, multinational study evaluating Tumor Treating Fields used together with pembrolizumab for patients with metastatic non-small cell lung cancer who were previously treated with a PD-1/PD-L1 inhibitor and platinum-based chemotherapy.
The company explains that the availability of real-world evidence will allow it to achieve the trial’s objectives without continuing this interventional clinical study. NovoCure states that this decision is not related to any safety concerns.
Capital World Investors (CWI) reports beneficial ownership of 6,382,848 shares of NovoCure Ltd. common stock, representing 5.7% of the 111,485,634 shares believed outstanding. CWI is identified as an investment adviser division of Capital Research and Management Company and related entities that provide investment management services under the name "Capital World Investors." The filing states CWI has sole voting and sole dispositive power over all 6,382,848 shares and that the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Schedule 13G/A amendment highlights: Capital International Investors (CII) reports beneficial ownership of 0 shares of NovoCure Ltd. (NVCR) common stock as of the event date 06/30/2025. This represents 0.0 % of the issuer’s 111,485,634 outstanding shares. All voting and dispositive powers—sole or shared—are now listed as zero.
The filing classifies CII as an investment adviser (IA) under Rule 13d-1(b). The certification confirms the shares were held in the ordinary course of business and not for the purpose of influencing control. CII’s exit moves its ownership below the 5 % reporting threshold and effectively eliminates a prior institutional position in NovoCure.
Investor takeaway: A complete liquidation by a large asset manager can signal changing sentiment and may increase free float, potentially adding near-term supply to the market and reducing perceived institutional sponsorship. However, no other financial metrics or strategic updates for NovoCure are provided in this document.